Kirsty Hillier, MD, is an Assistant Professor of Pediatric Hematology/Oncology at NYU Grossman School of Medicine and an Attending Physician at Hassenfeld Children’s Hospital at NYU Langone. Dr. Hillier is a physician-scientist dedicated to…
The primary purpose of our project will be to provide education that is specific to adolescent females diagnosed with a bleeding disorder. Most of the information available in the bleeding community is gender specific to males, age specific to…
Federal:Fiscal Year 2026 Funding Update On November 12, after 43 days and the longest government shutdown in history, legislation was passed to fund most federal agencies at current levels through January 30.…
CSL recently announced the publication of five years’ worth of data from their HOPE-B clinical trial program, which has been investigating the company’s hemophilia B gene therapy Hemgenix® (etranacogene dezaparvovec). NBDF is sharing this research…
On December 4, 2025, Representatives Kean (R-NJ), Barragán (DCA), Miller-Meeks (R-IA), Auchincloss (D-MA), Fitzpatrick (R-PA), and Watson-Coleman (DNJ) reintroduced the Help Ensure Lower Patient (HELP) Copays Act to make necessary…
Hemab Therapeutics recently announced positive results from a Phase 2 clinical study of their investigational subcutaneous therapy sutacimig. Sutacimig is a laboratory-engineered bispecific antibody being developed as the first-ever…
The National Bleeding Disorders Foundation (NBDF) is delighted to announce that Luke Luckey of Manchester, Michigan, was selected as the recipient of the 2025 Kevin Child Scholarship (KCS). The Child family selected Luke as this year’s KCS award…
(Editors note: January 22, 2026. Following publication of this joint statement from the National Bleeding Disorders Foundation (NBDF) and the World Federation of Hemophilia (WFH), NBDF received an additional letter from Pfizer. The company stated in…